Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Leiomyosarcoma

Leiomyosarcoma

19

Pipeline Programs↗

17

Active Trials↗

16

Companies Involved↗

Leiomyosarcoma is an emerging landscape with 19 programs across 16 companies. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

22/100

Mech. Concentration

20/100

Completion Rate

72/100

Attrition Rate

16/100

Pipeline

Programs by Phase

Preclinical5

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Epirubicin

Pfizer

Docetaxel Plus Gemcitabine

Memorial Sloan Kettering Cancer Center

Olaparib

AstraZeneca

Pazopanib

Novartis

Phase 12

Eribulin

Eisai

Nab-Sirolimus

Mirati Therapeutics Inc.

Phase 28

Talimogene Laherparepvec

Amgen

Ivonescimab

Summit Therapeutics

Gemcitabine

Johnson & Johnson

Rucaparib

Bristol-Myers Squibb

Nivolumab

Bristol-Myers Squibb

Phase 34

Doxorubicin

Pfizer

Trabectedin

Apotex Inc.

Lurbinectedin

Jazz Pharmaceuticals

Doxorubicin Hydrochloride

Pfizer

Approved

No programs

Analysis

Modality Breakdown

79%

Small molecule

15 of 19 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 19 classified programs, each share of the total. Modality classified for 100% of 19 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed21 · 42%

Recruiting13 · 26%

Terminated5 · 10%

Unknown status4 · 8%

Active, not recruiting3 · 6%

Withdrawn3 · 6%

Other1 · 2%

Clinical Trials

Trial Activity

50 trials

Vonescimab for the Treatment of Previously Treated Advanced or Unresectable Leiomyosarcoma - a Phase II Trial

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07516925·20 enrolled

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in Uterine Leiomyosarcoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07076186·48 enrolled

A Randomized Phase II Study of Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

Recruiting·GGOG Foundation·Phase 2·NCT05649956·40 enrolled

Pilot Study of ctDNA and Imaging Characteristics as Biomarkers of Disease-related Outcomes in Patients With Localized Leiomyosarcoma Receiving Chemotherapy

Recruiting·UUniversity of Michigan Rogel Cancer Center·N/A·NCT04925089·40 enrolled

Observational Study of Biomarkers of Disease-related Outcomes in Patients With Metastatic Leiomyosarcoma Receiving Chemotherapy

Recruiting·UUniversity of Michigan Rogel Cancer Center·N/A·NCT05653388·200 enrolled

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Recruiting·—·Phase 2·NCT06528769·16 enrolled

A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06308419·18 enrolled

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting·IItalian Sarcoma Group·Phase 2·NCT04383119·100 enrolled

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Recruiting·WWashington University School of Medicine·Phase 1·NCT06957431·18 enrolled

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Recruiting·NNorthwestern University·Phase 2·NCT06571734·29 enrolled

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT07125183·20 enrolled

Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

Recruiting·PPharmaMar·Phase 3·NCT06088290·450 enrolled

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting·UUNICANCER·Phase 2·NCT06524583·198 enrolled

A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02923778·40 enrolled

A Randomized Phase 2/3 Study of Olaparib Plus Temozolomide Versus Investigator's Choice for the Treatment of Patients With Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy

Active, not recruiting·National Cancer Institute (NCI)·Preclinical·NCT05432791·74 enrolled

Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)